Content Type: Article

  • CFPB Proposes Rule Defining Larger Participants of a Market for General-Use Digital Consumer Payment Applications

    CFPB Proposes Rule Defining Larger Participants of a Market for General-Use Digital Consumer Payment Applications

    ARTICLE / CLIENT ALERT

    CFPB Proposes Rule Defining Larger Participants of a Market for General-Use Digital Consumer Payment Applications

    November 16, 2023

    Read time: 9 min

    Key takeaways
    Overview

    On Nov. 7, 2023, the Consumer Financial Protection Bureau (“CFPB”) issued a proposed rule (“Proposed Rule”) which would establish the CFPB’s supervisory authority over nonbank covered persons that are larger participants in the market for general-use digital consumer payment applications.[1] Covered persons would be subject to supervision for compliance with federal consumer financial laws, such as the Consumer Financial Protection Act and its prohibition against unfair, deceptive and abusive acts or practices, the privacy provisions of the Gramm-Leach-Bliley Act and Regulation P, and the Electronic Fund Transfer Act and Regulation E.[2]

    The issuance of this Proposed Rule is the CFPB’s latest effort to supervise nonbank providers of consumer financial products and services and is targeted at certain popular consumer payment applications, like Apple Pay, Google Pay and Venmo. While some providers captured by the Proposed Rule may already be subject to supervision by the CFPB for other products and services, like international remittance transfer services, the Proposed Rule would bring certain payments companies not otherwise subject to CFPB supervision directly under its examination and supervisory authority. The Proposed Rule would be the sixth in a series of CFPB rulemakings to define larger participants operating in markets for consumer financial products and services.[3]

    Key Terms

    “Market” Definition. The Proposed Rule would define a market for consumer financial products or services as providing a covered payment functionality through a digital application for consumers’ general use in making consumer payment transactions.[4]

    “Covered Payment Functionality” Definition. The Proposed Rule would cover two types of payment functionalities: funds transfer functionality and wallet functionality. The Proposed Rule clarifies that a nonbank’s level of involvement in the market would not be based on which covered payment functionality is used. Rather, the CFPB would base it on the annual covered payment transaction volume.[5] The Proposed Rule would treat the two payment functionalities as a single market for general-use digital consumer payment applications because these two payment functionalities serve the same common purpose for consumers.[6]

    The Proposed Rule would define funds transfer functionality as receiving funds for the purpose of transmitting them, or accepting and transmitting payment instructions.[7] These types of transactions are often referred to as peer-to-peer or P2P transfers. A wallet functionality would include a product or service that stores account or payment credentials, and transmits, routes or processes stored account or payment credentials to facilitate a consumer payment.[8]

    “General Use” Definition. The Proposed Rule would define general use as digital applications without significant limitations on the purpose of consumer payment transactions facilitated by the covered payment functionality. The Proposed Rule would seek to confine the market to digital payment applications that consumers can use for a wide range of purposes.[9] The Proposed Rule notes that a general use digital application allows consumers to complete broad functions, such as sending funds to friends and family, buying a wide range of goods and services at different stores, or both.[10] The Proposed Rule explains the term general use will even apply to digital applications that have a fixed universe of potential recipients. Under the Proposed Rule, general use includes digital applications that allow consumers to transfer funds to friends or family in jail because the recipient can use the funds for a variety of purposes, such as purchasing food, toiletries, medical supplies or phone credits.[11] The Proposed Rule excludes from the general use definition digital applications solely to purchase or lease a specific type of service, good or other property, such as: transportation, lodging, food, an automobile, real property, or consumer financial products and services.[12] The Proposed Rule also excludes accounts that are expressly excluded from the definition of “prepaid account” as defined in Regulation E, such as tax-advantaged health medical spending accounts and gift cards,[13] applications to pay a specific debt or type of debt, and applications for bill splitting. [14]

    “Consumer Payment Transactions” Definition. The Proposed Rule would define covered payment transaction to mean the transfer of funds on behalf of a consumer physically located in a state to another person primarily for personal, family or household purposes.[15] Consumer payment transactions encompass consumer funds transfers and transfers made by extending consumer credit as a part of a consumer credit transaction.[16] For purposes of the Proposed Rule, funds would include crypto-assets that “can be easily purchased in exchange for ordinary currency, acts as a denominator of value, and is used to conduct financial transactions.”[17]

    In addition, the transfer of funds must be made to another person besides the consumer, such as another consumer or business.[18] This component of the Proposed Rule would exclude transfers between a “consumer’s own deposit accounts, transfers between a consumer deposit account and the same consumer’s stored value account held at another financial institution.”[19] The consumer must also be physically located in a State at the time of the payment transaction. Thus, the proposed market definition does not include payments initiated by a consumer physically located in a foreign country.[20]

    The Proposed Rule clarifies the scope of the proposed market by exempting the following types of transactions: (i) an international money transfer; (ii) a transfer of funds that is either (a) linked to the consumer’s receipt of a different form of funds, such as a currency exchange transaction, or (b) excluded from the definition of “electronic fund transfer”; (iii) a payment transaction for the sale or lease of goods or services that a consumer selected from an online or physical store or marketplace; and (iv) an extension of consumer credit made using a digital application.[21]

    The Proposed Rule notes the online marketplace exclusion in subparagraph (iii) is “descriptive of the narrow role that many merchants play in processing consumer payments or financial data.”[22] Notably, the online marketplace exclusion does not apply if a merchant or online marketplace uses consumer financial data for any purpose other than initiating a payments transaction, such as data monetization, targeted marketing or research purposes.[23] The online marketplace exclusion also does not apply “if an online marketplace operator’s digital consumer application processes payments or other financial data associated with the consumer’s purchase of goods or services at unaffiliated online or physical stores or third-party goods or services on the operator’s online marketplace.”[24] Since many online marketplaces sell third-party goods or services, clarification appears necessary to ensure that the online marketplace exclusion is properly tailored and available to e-commerce marketplace operators with third-party sellers.

    Larger Participants Test. The Proposed Rule would establish a two-part test to determine whether a nonbank covered person is a larger participant in the market for general-use digital consumer payment applications. The nonbank covered person and its affiliated companies must: (1) provide covered consumer payment transactions of at least five million transactions in the preceding calendar year by providing general-use digital consumer payment applications, and (2) during the preceding calendar year, the nonbank covered person was not a small business concern.[25] A nonbank covered person would be a small business concern if its size were at or below the standard for its primary industry as defined by the Small Business Administration.[26] As prescribed by existing regulation, nonbank covered persons that qualify as a larger participant would remain a larger participant until two years from the first day of the tax year in which the person last met the larger-participant test.[27]

    Persons interested in submitting a comment to address the Proposed Rule must submit the comment on or before Jan. 8, 2024, or 30 days after publication of the Proposed Rule in the Federal Register, whichever is later.

    Schulte Roth & Zabel’s lawyers are available to assist you in preparing a comment or addressing any questions you may have regarding these developments. Please contact the Schulte Roth & Zabel lawyer with whom you usually work, or any of the following attorneys:

    Donald J. Mosher – New York (+1 212.756.2187, donald.mosher@srz.com)

    Betty Santangelo – New York (+1 212.756.2587, betty.santangelo@srz.com)

    Melissa G.R. Goldstein – Washington, DC (+1 202.729.7471, melissa.goldstein@srz.com)

    Kara A. Kuchar – New York (+1 212.756.2734, kara.kuchar@srz.com)

    Adam J. Barazani – New York (+1 212.756.2519, adam.barazani@srz.com)

    Jessica Romano – New York (+1 212.756.2205, jessica.romano@srz.com)

    Jessica Sklute – New York (+1 212.756.2180, jessica.sklute@srz.com)

    Noah N. Gillespie – Washington, DC (+1 202.729.7483, noah.gillespie@srz.com)

    Jesse Weissman – New York (+1 212.756.2460, jesse.weissman@srz.com)


    [1] Available here.

    [2] Proposed Rule at 14-15.

    [3] The CFPB issued 12 CFR § 1090.104 regarding the consumer reporting market; 12 CFR § 1090.105 regarding the consumer debt collection market; 12 CFR § 1090.106 regarding the student loan servicing market; 12 CFR § 1090.107 regarding the international money transfer market; and 12 CFR § 1090.108 regarding the automobile financing market.

    [4] Proposed Rule at 15.

    [5] Id. at 27.

    [6] Id.

    [7] Id. at 28.

    [8] Id. at 29.

    [9] Id. at 34.

    [10] Id.

    [11] Id. at 35-36

    [12] Id.at 68.

    [13] 12 CFR 1005.2(b)(3)(ii).

    [14] Id. at 68.

    [15] Id. at 16.

    [16] Id. at 18.

    [17] Id at 18-19.

    [18] See, e.g., Proposed Rule at 20.

    [19] Id. at 20.

    [20] Id.

    [21] Id. at 17.

    [22] Id. at 25.

    [23] Id.

    [24] Id. at 26.

    [25] Id.at 68-67.

    [26] Id. at 43; The Small Business Administration establishes size standards by considering “economic characteristics comprising the structure of an industry, including degree of competition, average firm size, start-up costs and entry barriers, and distribution of firms by size.” 13 CFR 121.102.

    [27] Proposed Rule at 8; see also 12 CFR 1090.102.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2023 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Donald J. Mosher

    Partner

    New York – 919 Third Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Adam J. Barazani

    Partner

    New York – 919 Third Avenue

    More insights

  • New York Withdraws Proposed Market Conduct Regulations for PBMs, Adopts Licensure Rules

    New York Withdraws Proposed Market Conduct Regulations for PBMs, Adopts Licensure Rules

    ARTICLE / CLIENT ALERT

    New York Withdraws Proposed Market Conduct Regulations for PBMs, Adopts Licensure Rules

    November 15, 2023

    Read time: 5 min

    Key takeaways
    Overview

    On October 31, 2023, the New York State Department of Financial Services (DFS) released a notice withdrawing its proposed market conduct rules for pharmacy benefit managers (PBMs). The proposed rules, announced August 16, 2023, would have significantly increased the state’s oversight of PBMs. At the same time, DFS finalized licensure rules for PBMs, to be effective November 15, 2023.

    In depth

    PROPOSED MARKET CONDUCT RULES

    Before withdrawing them, DFS described the proposed market conduct rules as “the most comprehensive set of market conduct rules for pharmacy benefit managers in the country.” Proposed areas of regulation included:

    • Contracting with network pharmacies
    • Prohibiting preferential treatment of pharmacies owned or affiliated with PBMs
    • Requiring prior approval for acquisitions of PBMs
    • Imposing consumer protection requirements such as prohibiting market conduct practices deemed unfair, deceptive or abusive
    • Requiring network adequacy standards

    A full summary of the proposed market conduct rules is available in our previous article here.

    The notice of withdrawal states DFS is “reconsidering” the proposed rules. Although the withdrawal and reconsideration does not eliminate the possibility of re-proposal, it does mean that the proposed January 2024 effective date will no longer apply. DFS did not provide any additional information regarding the withdrawal.

    LICENSING OF PBMs RULE

    DFS finalized a different proposed rule regulating PBM licensure, effective November 15, 2023. The Licensing of Pharmacy Benefit Managers Rule does not overlap substantively with the proposed market conduct rules, except that it adopts several definitions that were also proposed in the proposed market conduct rules.

    The Licensing of PBMs Rule also addresses:

    • Assessments for DFS operating expenses. The rule sets forth how PBMs licensed or registered pursuant to New York Insurance Law Article 29 will be assessed by the DFS superintendent for the operating expenses of DFS that are attributable to regulating PBMs. Licensed and registered PBMs will be billed five times per year, consisting of four quarterly assessments (each approximately 25% of the anticipated annual amount of operating expenses), with a final true-up assessment based on the actual total operating cost for the fiscal year. The rule details how assessments will be computed and provides penalties for non-compliance. The rule also sets forth a process for special assessments to an individual licensee or registrant when the DFS superintendent determines that the expenses associated with a specific examination, investigation or review are best allocated solely to an individual licensee or registrant subject to such examination or investigation.
    • Filings and requirements for issuing and maintaining a PBM license. The rule sets forth the information and documentation required to be provided with the initial license application. The rule also requires that changes to information and documentation contained in the initial license application be reported to DFS within 30 days of the change. Required documentation includes company organizational documents, bylaws or other documents governing the internal affairs of the PBM, as well as lists of pharmacists, pharmacies, pharmacy administrative services organizations, rebate aggregators, switch companies, wholesalers and health plans with which the PBM contracts, including identifying whether the PBM has ownership interests in, or affiliations with, such entities. The rule also requires PBMs to comply with certain cybersecurity requirements and file for a certification of compliance with these requirements prior to applying for a license.
    • Reporting and recordkeeping requirements. The rule also sets forth reporting and recordkeeping requirements for PBMs. Records that must be maintained include copies of any document necessary to respond to a health plan’s request for an accounting pursuant to 11 NYCRR Part 452; records of health plan requests for an accounting pursuant to 11 NYCRR Part 452; copies of audited financial statements; and all documents and information related to or used in denying a maximum allowable cost appeal under New York Public Health Law 280-a(4)(E). The rule sets forth timeframes for document retention of these records and requires PBMs to provide copies of such records to DFS within 15 business days of a request from DFS. Finally, the rule sets forth standards for the maintenance and reproduction of records, including requiring PBMs to maintain and establish a records-retention plan to safeguard against the alteration of records.

    LOOKING AHEAD

    Stakeholders should continue to monitor regulatory activity in New York related to PBMs, particularly as the new legislative session begins in January 2024.

    Please contact the authors or your regular McDermott lawyer with any questions related to New York’s PBM regulations.

    Authors

    Gregory R. Mitchell

    Partner

    New York – One Vanderbilt Avenue

    Grayson I. Dimick

    Associate

    Washington, DC

    More insights

  • OIG Issues General Compliance Program Guidance Updates

    OIG Issues General Compliance Program Guidance Updates

    ARTICLE / CLIENT ALERT

    OIG Issues General Compliance Program Guidance Updates

    November 15, 2023

    Read time: 11 min

    Key takeaways
    Overview

    On November 6, 2023, the US Department of Health and Human Services (HHS) Office of Inspector General (OIG) published the General Compliance Program Guidance (GCPG) as a revised reference guide for the healthcare compliance community and other healthcare stakeholders. The GCPG is part of the ongoing OIG modernization initiative announced on April 24, 2023, and summarizes the federal laws, OIG resources and compliance program infrastructure. The GCPG is provided as a nonbinding, voluntary guidance document for the healthcare community.

    In depth

    OIG COMPLIANCE PROGRAM GUIDANCE DOCUMENTS

    From 1998 to 2008, OIG developed a series of voluntary compliance program guidance documents (CPGs) directed at various centers of the healthcare industry. On April 24, 2023, OIG announced plans to improve and update existing CPGs and deliver new CPGs specific to new segments of the healthcare industry through the OIG’s modernization initiative. On November 6, 2023, OIG released the first new CPG since September 2008: the GCPG. Given the GCPG’s 91-page length, we identify the highlights here and do not cover every issue or suggestion OIG discusses.

    OIG clarified that it will no longer publish updated or new CPGs in the Federal Register and will instead post them directly on the OIG website. The GCPG is applicable to all individuals and entities in the healthcare industry. Starting in 2024, OIG will publish industry-specific CPGs (ICPGs) for different types of providers, suppliers and other participants. When OIG lawyers announced the GCPG at the Health Care Compliance Association’s Enforcement Compliance Conference, they stated that managed care and nursing homes will be the first ICPGs published. The existing CPGs will remain effective until replaced and then most likely will be archived on OIG’s website.

    While the GCPG is voluntary guidance, and OIG has repeatedly emphasized the voluntary and nonbinding nature of the guidance, OIG and other government agencies, as well as the healthcare community, have often used past OIG CPGs as the basis for structuring compliance programs and evaluating compliance program effectiveness.

    THE GENERAL COMPLIANCE PROGRAM GUIDANCE

    The GCPG (a) summarizes key federal authorities for entities engaged in health care business; (b) provides a revised version of the seven elements of a compliance program; (c) lists adaptations for small and large entities; (d) identifies other compliance considerations, and (e) lists OIG processes and resources.

    Key Federal Authorities

    The GCPG summarizes federal laws related to healthcare fraud enforcement and other standards. These key authorities include the federal Anti-Kickback Statute (AKS), the physician self-referral law (known as the Stark Law), the False Claims Act, civil monetary penalty authorities, exclusion authorities, the criminal Health Care Fraud Statute, and Health Insurance Portability and Accountability Act (HIPAA) privacy and security rules. The GCPG includes examples of problematic conduct, key questions that entities can ask to evaluate AKS risk in an arrangement, and tips on what to do if a problem is identified. OIG notes that because of increasing cybersecurity attacks, compliance with privacy, security and breach notification rule requirements should be a top compliance priority for HIPAA-regulated entities of all sizes.

    Compliance Program Infrastructure: The Seven Elements

    The GCPG largely maintains the historic seven elements of a compliance program from prior CPGs, but it provides a more in-depth discussion of each element while being agnostic to the specific facility type. The revised guidance integrates feedback from industry stakeholders and “lessons learned” from enforcement actions, 25 years of Corporate Integrity Agreement monitoring, investigations and evolving technologies used to support the healthcare delivery system.

     

    Prior Seven Elements New Seven Elements
    Written Policies and Procedures Written Policies and Procedures
    Designated Compliance Officer and Compliance Committee Compliance Leadership and Oversight
    Training and Education Training and Education
    Effective Lines of Communication Effective Lines of Communication with the Compliance Officer and Disclosure Program
    Enforcing Standards Through Well-Publicized Disciplinary Guidelines Enforcing Standards: Consequences and Incentives
    Internal Monitoring and Auditing Risk Assessment, Auditing and Monitoring
    Responding Promptly to Detected Deficiencies and Undertaking Corrective Action Responding to Detected Offenses and Developing Corrective Action Initiatives

    Some themes that OIG identifies include:

    • Tone from the Top: OIG states that boards should take every opportunity to communicate to each of its audiences its commitment to compliance. To demonstrate such commitment, the board and chief executive officer (CEO) may wish to include a signed endorsement or similar written statement with their code of conduct, which should be updated after leadership changes to reflect the ongoing commitment to compliance.
    • Chief Compliance Officer (CCO) Has a Senior Role: OIG spends a considerable amount of time discussing the CCO’s role as a senior leader in the organization who has the authority, stature, access and resources necessary to lead an effective and successful compliance program.
      • OIG notes that the CCO’s primary responsibilities should include advising the CEO, board and other senior leaders on compliance risks and business strategy.
      • OIG maintains its long-held position that the CCO should not lead or report to the entity’s legal or financial functions, and the CCO should maintain a degree of separation from the entity’s delivery of healthcare items and services, including billing, coding and claim submission. This is true even for small entities that may have a compliance contact rather than a CCO.
    • Well-Functioning Executive Compliance Committee: The executive compliance committee should be chaired by the CCO and composed of various leaders across the organization. In addition to the usual suspects, such as legal, audit and human resources, OIG includes clinical and quality as recommended compliance committee members.
      • OIG suggests including “attendance, active participation and contributions” as part of the members’ performance plan and compensation evaluation, and suggests that the CCO report on member attendance to the board compliance committee.
      • OIG lists indicators of a well-functioning committee, such as a robust and detailed work plan, follow-through on committee recommendations and active engagement of committee members.
      • OIG describes in some detail how to conduct the risk assessment process and auditing and monitoring activities.
    • Engaged Board Compliance Committee: OIG suggests that the board compliance committee actively oversee the compliance program function and evaluate the risk assessment process. OIG states that the board compliance committee should reserve time at each meeting to discuss the compliance program, activities and risk updates with the CCO.
    • Targeted Training and Multiple Forms: OIG recommends developing targeted compliance training for different types of employees to address compliance risks specific to those roles. Board members should also receive compliance training. OIG also suggests that training occur in multiple forms, including both formal training sessions and more informal methods, such as periodic videos, newsletters, standing agenda items in staff meetings and other ad hoc communications.
    • Multiple Reporting Pathways: Entities should facilitate multiple independent reporting pathways to report compliance concerns, not just one way or a “preferred” pathway. Entities should avoid requesting or requiring that personnel bring such concerns to their manager or supervisor before contacting the compliance officer. Such a request may deter individuals from coming forward or increase potential for reports to be diverted by supervisors or other personnel.
    • Incentives for Compliant Behavior: Entities should consider encouraging participation in the compliance program through incentives, such as sharing stories of compliance success or how issues were resolved, or recognizing an individual (even anonymously) whose actions resulted in mitigation of harm or risk through performance reviews.

    The US Department of Justice (DOJ) has also compiled a set of questions for entities to consider in setting up and reviewing their system of policies and procedures.

    Compliance Program Adaptations for Small and Large Entities

    While the GCPG is applicable to all entities, OIG provides guidance on how small entities and large organizations should think about how to “right-size” their compliance programs to meet their own entity’s needs.

    For small organizations with more limited resources, in keeping with its prior guidance, OIG recognizes that such entities may face financial and staffing constraints that are not as material for larger entities. OIG’s suggestions for small organizations on how to implement the seven elements include designating a compliance contact if a compliance officer cannot be hired; making clear that if anonymity of an employee’s identity cannot be guaranteed, there are protections in place for individuals reporting concerns; and identifying risk indicators particularly relevant to the business.

    For large entities, OIG recommends that board members consider the size and complexity of the organization in reviewing the scope and adequacy of the compliance program. Because large entities may have greater resources, larger staffs and multiple locations, compliance subcommittees may be needed. If the entity has a global parent or board, the US-based compliance officer and committee should regularly engage with the global board, and the entity may wish to consider engaging counsel knowledgeable in the laws applicable to the US organization. OIG further suggests that large organizations consider having separate board healthcare compliance and audit committees.

    Other Compliance Considerations

    Adding Quality: While quality and patient safety often are treated separately from compliance, the GCPG states that these issues are high priorities for HHS and DOJ and should be incorporated into compliance programs. The compliance committee should include members responsible for quality assurance and patient safety, and should receive regular reports from senior leadership on those topics.

    New Entrants: OIG notes that it is “seeing an increasing number of new entrants” in the healthcare sector, such as technology companies, social services organizations and private equity investors. OIG recommends that new entrants take steps to ensure they are familiar with the healthcare regulatory landscape, as “business practices that are common in other sectors create compliance risk in health care.” OIG expresses concerns about the impact of ownership incentives of private equity and other forms of investment on the delivery of high-quality and efficient healthcare. OIG advises entities with private investments to carefully scrutinize their operations and incentive structures—“follow the money”—to ensure that there are checks and tracking systems in place to prevent prioritizing financial gain over patient care.

    Financial Arrangement Monitoring: OIG incorporated elements from Corporate Integrity Agreements that address AKS issues to suggest entities not only have a process for entering into financial arrangements with referral sources but also have a process to monitor compliance with those arrangements. This monitoring process should consider establishing a centralized arrangements tracking system, a process to ensure that proper supporting documentation is maintained, regular legal reviews are conducted, and fair market value assessments are performed and updated routinely as appropriate.

    OIG Resources and Processes

    The GCPG’s final section provides several compliance and legal resources, including compliance toolkits, trainings, software recommendations, advisory opinions, special fraud alerts, FAQs, and other reports and publications.

    Additional Resources Referenced

    TAKEAWAYS
    Compliance is a dynamic process, and an effective compliance program is critical to operational success and prevention of fraud, waste and abuse. The GCPG should assist healthcare entities and those playing a role in healthcare delivery today in evaluating and structuring compliance programs. Many of OIG’s suggestions are consistent with prior compliance program guidance or reflect recent Corporate Integrity Agreements and other common industry practices.

    At the same time, the GCPG goes farther in certain areas than OIG has in the past, particularly on governance issues relating to the CCO’s role and placement in the organization, and the executive compliance committee’s activities and scope, including making quality part of the compliance committee’s work. OIG defines “quality” in the context of both manufacturing and supplying drugs, devices and other items, as well as the provision of items and services by healthcare providers. In many healthcare organizations, clinical quality and patient/product safety is overseen by specific board-level quality committees working in concert with departmental operations that involve clinicians and others who have specialized clinical and quality program knowledge. This collaborative approach creates a typical healthcare quality infrastructure, which is designed in part to meet other regulatory requirements For hospitals, these requirements include CMS’ Conditions of Participation for Hospitals, accrediting organization standards, and related requirements around quality assurance and performance improvement programs. For life sciences companies, these requirements include FDA’s Current Good Manufacturing Practices regulations (as well as other country’s manufacturing standards). Including the CCO and compliance committee in an organization’s existing quality committee and departmental structure without careful planning risks inefficiency, redundancy, and role confusion. The ICPGs will hopefully provide further recommendations on the interplay between the compliance and quality functions for various types of healthcare businesses to assist healthcare organizations in evaluating their structures and operations.

    The GCPG’s express discussion of new entrants such as technology companies (both large and start-up) and private equity provides further confirmation that OIG is increasing its scrutiny of those new entrants’ companies and their activities as federal healthcare program participants.

    As always, your McDermott lawyers are available to discuss the GCPG and its application to your organization.

    Authors

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Monica Wallace

    Partner

    Chicago

    Nicholas F. Alarif

    Partner

    Washington, DC

    Sandra M. DiVarco

    Partner

    Chicago

    More insights

  • Remote Monitoring and Digital Therapies: CMS Updates Coverage and Payment Policies

    Remote Monitoring and Digital Therapies: CMS Updates Coverage and Payment Policies

    ARTICLE / CLIENT ALERT

    Remote Monitoring and Digital Therapies: CMS Updates Coverage and Payment Policies

    November 14, 2023

    Read time: 10 min

    Key takeaways
    Overview

    In recent years, the Centers for Medicare & Medicaid Services (CMS) has expanded payment for remote monitoring services in an effort to pay for non-face-to-face services that improve care coordination for Medicare beneficiaries. On November 2, 2023, CMS released the calendar year 2024 final rule for services reimbursed under the Medicare Physician Fee Schedule. In the final rule, CMS clarified certain guidance for remote monitoring services, finalized separate reimbursement for remote monitoring provided by rural health centers and federally qualified health centers, and discussed a recent request for information for digital therapies.

    In depth

    BACKGROUND

    Over the past several years, CMS has established separate reimbursement for a variety of care management services to recognize and pay for services not appropriately captured by existing codes for in-person patient encounters. Care management services are patient management and support services that are provided by or under the direction of a physician or qualified healthcare professional. Remote monitoring is a type of care management service that uses digital technologies to collect medical and other health data from patients remotely and transmits the information electronically to the patient’s healthcare provider for assessment. Remote monitoring is typically used between in-person visits with a healthcare practitioner, and the data collected is used to formulate, update and manage the patient’s treatment plan.

    There are currently two distinct types of remote monitoring services that are reimbursable under the MPFS. Remote physiological monitoring (RPM) uses medical devices to obtain data, such as blood pressure and weight, and transmits it to healthcare providers for review and assessment. Remote therapeutic monitoring (RTM) uses non-physiological data to monitor a patient’s health or response to treatment, such as medication adherence, musculoskeletal activity or respiratory activity. Both services use a series of codes that account for initial setup and patient education on the remote monitoring device, transmission of data, and interpretation and analysis of the data by the patient’s healthcare provider.

    During the public health emergency (PHE) for the COVID-19 pandemic, CMS issued certain waivers and flexibilities that permitted more patients to receive remote monitoring services.

    GENERAL CLARIFICATIONS ON REMOTE MONITORING PAYMENT POLICIES

    As previewed by preamble commentary related to the PHE flexibilities for remote monitoring services, CMS did not extend the waivers and flexibilities for remote monitoring services furnished after the conclusion of the PHE on May 11, 2023. In response to questions from interested parties about billing scenarios and appropriate use of codes, CMS reiterated and clarified the following previously established policies related to remote monitoring services:

    • RPM services may only be furnished to established patients. However, if patients received initial monitoring services during the PHE, they can be considered established patients for purposes of the patient requirements effective after the end of the PHE.
    • Monthly remote monitoring services may be reported only once during a 30-day period.
    • Only one practitioner may bill under RPM or RTM codes during a 30-day period when at least 16 days of data are collected on at least one medical device (as defined by the Federal Food, Drug, and Cosmetic Act).
    • Practitioners can bill RPM or RTM codes concurrently with other care management services codes as long as time or effort is not counted twice. However, RPM and RTM codes may not be billed together, even if multiple devices are used.

    CMS also responded to comments on proposed clarifications and feedback related to RPM and RTM services, confirming the following:

    • CMS has not specified in prior rulemaking whether RTM services require an established patient relationship (as required with RPM services) but states in this final rule that there does not need to be an established patient relationship for RTM services. However, CMS expects RTM services will be furnished to a patient after an initial interaction between the patient and the billing practitioner and that RTM services will be furnished consistent with a treatment plan established during that initial interaction The agency intends to clarify this point in future rulemaking.
    • Billing practitioners who receive a global service payment for surgery are prohibited from billing for RPM or RTM services furnished during the global period. However, practitioners (such as physical and occupational therapists) are permitted to furnish RPM or RTM services during the global period if the provider did not furnish the global procedure and thus did not receive the global service payment.
    • Addressing an erroneous statement published in the proposed rule, CMS clarified that the 16-day data collection requirement does not apply to Current Procedural Terminology (CPT®) codes for certain remote monitoring treatment management services, including 99457, 99458, 98980 and 98981, which account for time spent in a calendar month.

    PUBLIC COMMENTS IN RESPONSE TO CMS’ REQUEST FOR INFORMATION ON DIGITAL THERAPIES

    In the MPFS proposed rule, CMS requested information on digital therapies, including digital cognitive behavioral therapy (CBT). As previously noted, although CMS has established Medicare payment rates for remote monitoring services, CMS has not established reimbursement for other types of digital therapies. In recent years, the US Food and Drug Administration (FDA) has reviewed and cleared several mobile medical applications that are intended to address specific health conditions and generally require a prescription or referral from a clinician. CMS sought information from stakeholders to better understand how digital technology is used in clinical practice and how that affects coding and payment.

    Commenters noted the existing CMS authority to pay for durable medical equipment (DME) and services that are furnished “incident to” healthcare professionals’ services. Stakeholders encouraged CMS to use authority under these benefit categories to establish payment for digital therapeutics cleared by the FDA with other prescription medical devices that fall under existing benefit categories. Commenters also encouraged CMS to establish a separate set of G-codes to account for scenarios when digital therapeutic devices are acquired by a Medicare-enrolled practitioner and furnished to a patient.

    CMS noted that existing RTM codes include monitoring patient adherence and therapy response for use with CBT and, in 2022, established a contractor-priced CPT code for the supply of a device for CBT monitoring. CMS recognized the new coding proposals on the public agenda for the September 2023 CPT Editorial Panel to allow for reporting of digital CBT, remote therapeutic treatment and other digital therapies as incident to services. Moreover, CMS expressed continued interest in feedback related to this topic, including commentary about any potential codes for review through the existing American Medical Association processes and considerations for future rulemaking that would improve the accuracy of coding and payment under the MPFS. The response did not rule out consideration for G-codes as part of proposals to improve the accuracy of payment. CMS also recognized that for a digital therapeutic item to be designated DME, it must meet the Medicare regulatory definition of DME, as articulated in 42 C.F.R § 414.202.

    REIMBURSEMENT FOR REMOTE MONITORING SERVICES FURNISHED BY RHCS AND FQHCS

    When RPM and RTM services are furnished incident to a visit at an RHC or FQHC, payment is included in the all-inclusive rate paid to the RHC for all medically necessary services furnished to a patient on the same day, while FQHCs are paid under a prospective system. RHCs and FQHCs requested a separate payment for RTM and RPM services, specifically to improve access to services in rural and underserved areas, to reimburse for setup and patient education, and to account for monthly data transmission. In an effort to improve payment for care management and coordination, CMS has updated its payment policies and is establishing separate payment for monthly care management and behavioral health integration services that are not accounted for in the existing payment methodologies for RHCs and FQHCs.

    Specifically, the CPT codes for RPM and RTM services will now be eligible for reimbursement under an existing Healthcare Common Procedure Coding System (HCPCS) code, G0511, that corresponds to general care management services. Although all commenters were supportive of CMS’s proposal to allow reimbursement for RPM and RTM services, some requested separate codes for RPM and RTM services that would be equivalent to the national average payment rate for these services under the MPFS.

    The current reimbursement available under HCPCS code G0511 is based on the MPFS national average non-facility payment rate for each of the services identified as billable general care management services. Each payment rate is added and divided by the total number of codes to reach the payment amount for G0511. However, with the increased volume of CPT codes for care management services that have been recognized for reimbursement under G0511, CMS acknowledged that the payment amount calculation may not reflect the full cost of non-face-to-face work involved in furnishing a broad array of care management services.

    In the final rule, CMS established a revised payment methodology for G0511 that calculates the payment rate based on the actual utilization of services using a weighted average. Because RPM and RTM are not yet utilized under the general care management code, utilization data included in the new calculation methodology is sourced from the MPFS. The new calculation methodology increases the weighted average to $72.98, which CMS believes matches the value of RPM and RTM services.

    On an annual basis, CMS plans to obtain actual utilization data regarding the services that comprise G0511 using available data for services paid under the MPFS and to calculate a weighted average by multiplying the non-facility payment rate times the non-facility utilization for each code, then dividing the total by the summed non-facility utilization for codes included in the average.

    To bill for services under the general care management code, RPM and RTM services must be medically reasonable and necessary, meet all requirements, and not duplicate services paid to RHCs and FQHCs under the general care management code for an episode of care in a calendar month. CMS clarified that RHCs and FQHCs may bill the general care management code multiple times in a calendar month, provided all requirements are met and resource costs are not duplicated.

    SUPERVISION REQUIREMENTS FOR RTM SERVICES BILLED BY PHYSICAL AND OCCUPATIONAL THERAPISTS

    Under existing regulations for services furnished by occupational therapists (OTs) and physical therapists (PTs) in private practice, all services furnished by occupational therapist assistants (OTAs) and physical therapist assistants (PTAs) must be performed under the direct supervision of the supervising OT or PT. These regulations make it difficult for PTs or OTs to bill for RTM services performed by OTAs and PTAs, even though private practice PTs and OTs are expected to be some of the primary utilizers of RTM services.

    In an effort to increase access to RTM services furnished by PTAs and OTAs, CMS finalized a regulatory change to permit PTs and OTs in private practice to provide general supervision to PTAs and OTAs who furnish RTM services. Of note, this regulatory change does not extend to PTs and OTs who are not enrolled in Medicare. Accordingly, only an OT or PT who is enrolled in Medicare may provide general supervision to an OTA or PTA who is furnishing RTM services. Any services furnished by an OT or PT who is not enrolled in Medicare still require direct supervision by a Medicare-enrolled OT or PT.

    KEY TAKEAWAYS

    Over the past several years, CMS has established separate reimbursement for RPM and RTM services in an effort to expand access to virtual care services that have the potential to significantly improve care management. This trend continues with the final rule, particularly with the establishment of reimbursement for RPM and RTM services furnished by RHCs and FQHCs. Similarly, the change in supervision requirements for RTM services furnished by OTs and PTs has the potential to further expand access to these services.

    However, despite recognition of the value of RPM and RTM services, CMS has reiterated that the COVID-19 PHE flexibilities have not been extended. CMS remains interested in the use of remote monitoring for CBT, and stakeholders should continue to monitor for new developments and provide feedback.

    Mary Ryan, a law clerk in McDermott’s Washington, DC office, also contributed to this article. 

    Authors

    Caroline Reignley

    Partner

    Washington, DC

    Michael W. Ryan

    Partner

    Washington, DC

    More insights

  • HHS Issues Provider Information Blocking Disincentives Proposed Rule

    HHS Issues Provider Information Blocking Disincentives Proposed Rule

    CLIENT ALERT / INFORMATION BLOCKING

    HHS Issues Provider Information Blocking Disincentives Proposed Rule

    November 14, 2023

    Read time: 11 min

    Key takeaways
    Overview

    On October 30, 2023, the US Department of Health and Human Services (HHS) Office of the National Coordinator for Health Information Technology (ONC) and the Centers for Medicare & Medicaid Services (CMS) released a long-awaited proposed rule to implement a 21st Century Cures Act provision establishing penalties (called “appropriate disincentives”) for health care providers determined by the HHS Office of Inspector General (OIG) to have committed information blocking. Health care providers have been subject to the information blocking regulations since April 5, 2021, but there has been no enforcement mechanism under the Cures Act to date.

    In depth

    KEY TAKEAWAYS

    • While the HHS proposed rule moves the industry one step closer to enforcement of the information blocking regulations against health care providers, it would apply penalties only to health care providers that participate in certain Medicare programs and not to all health care providers that are covered actors under the information blocking regulations.
    • HHS has not proposed any disincentives for health care providers that do not participate in the Medicare Promoting Interoperability or Medicare Shared Savings Program (MSSP), or that serve a limited number of Medicare beneficiaries.
    • In a blog post accompanying the proposed rule, ONC was unequivocal about its position that “[i]nformation sharing is expected.” What remains unclear is the mechanics of how HHS will apply its proposed disincentives framework, and a close review of the proposed rule reveals several open questions.
    • Comments on the proposed rule are due January 2, 2024.

    For more information about ONC’s information blocking regulations, including who is a regulated actor, as well as important information blocking definitions and exceptions, see our Special Report. For a discussion of OIG’s final information blocking enforcement rule concerning the penalties for information blocking by health IT developers of certified health IT (certified health IT developers) and health information networks and health information exchanges (HIN/HIEs), plus OIG’s investigation and enforcement procedures, see our Special Report “A Million Reasons to Share: OIG’s Final Rule on Information Blocking Enforcement.”

    SUMMARY OF PROPOSED DISINCENTIVES

    The proposed rule would establish the following disincentives for certain Medicare-enrolled health care providers that OIG determines committed information blocking and referred to CMS. As discussed below, the ultimate financial impact of disincentives (if any) would vary in some instances based on Medicare reimbursement rather than on the severity of a health care provider’s alleged information blocking conduct or other factors related to interference with access, exchange or use of electronic health information (EHI). The proposed rule does not include disincentives for health care providers that are not enrolled in Medicare.

    Hospitals and Critical Access Hospitals

    HHS proposes to use the existing Medicare Promoting Interoperability Program for the meaningful use of certified electronic health record (EHR) technology to impose disincentives on eligible hospitals and critical access hospitals (CAHs). Under the proposed rule, an eligible hospital or CAH would not be a meaningful EHR user in an EHR reporting period if OIG refers, during the calendar year of the reporting period, its determination that the eligible hospital or CAH committed information blocking. As a result, a hospital would be unable to earn the three-quarters of the annual market basket increase, and a CAH would have its payment reduced to 100% of reasonable costs, down from 101%.

    HHS estimates that this proposal could result in a median disincentive amount of $394,353 and a 95% range of $30,406 to $2,430,766. Of note, the Promoting Interoperability Program does not apply to many other facilities, laboratories, long-term care hospitals and other care sites.

    Physicians and Other Clinicians Reimbursed Under the Medicare Physician Fee Schedule

    With some exceptions, clinicians reimbursed under the Physician Fee Schedule (PFS) must either participate in a Medicare Advanced Alternative Payment Model (AAPM) or achieve a threshold Merit-based Incentive Payment System (MIPS) performance score to avoid a downward adjustment to their PFS reimbursement. CMS currently calculates the MIPS performance score based on four performance categories: Quality (30%), Improvement Activities (15%), Promoting Interoperability (25%) and Cost (30%). Measures within the four performance categories are scored and combined to make up a clinician’s MIPS final score. Those who score higher than a performance threshold set by CMS for a reporting year (75 points for 2024) can earn a positive adjustment of up to 9% of reimbursement under the PFS in the payment year. Likewise, those below the performance threshold face penalties of up to -9% of reimbursement under the PFS. CMS applies a payment adjustment to the payment year two years after the calendar year of the clinician’s MIPS reporting period. Not all MIPS participants are required to report the Promoting Interoperability category. For example, there are exceptions for facility-based and hospital-based clinicians (e.g., emergency room physicians and providers in ambulatory surgical centers) as well as some small practices.

    Under the proposed rule, a clinician who participates in MIPS and is required to report on the Promoting Interoperability performance category would receive a zero score for the category if OIG refers, during the calendar year of the clinician’s reporting period, a determination that the clinician committed information blocking. Since the Promoting Interoperability performance category is currently 25% of the total MIPS score, 75 would be the highest score that the clinician could earn and would likely result in a penalty based on the current MIPS performance threshold for 2024. Those who do not report the MIPS Promoting Interoperability category would not be subject to any disincentives under this proposal.

    HHS estimates that the median individual disincentive amount could be a loss of $686 for a clinician, while an estimated median group of six clinicians could see a loss of $4,116, with a range of $1,372 to $165,326 for group sizes ranging from two to 241 clinicians.

    Medicare Shared Savings Program

    Clinicians can avoid having to participate in MIPS, or can have their reporting requirements reduced, by participating in the Medicare Shared Savings Program (MSSP). CMS is moving to align certified EHR reporting requirements for all MSSP participants with those of the MIPS Promoting Interoperability performance category beginning in the 2025 performance year.

    Because MSSP accountable care organizations (ACOs) are not yet required to report under the Promoting Interoperability program, CMS proposes a different disincentive in connection with the MSSP. Under the proposed disincentives rule, if OIG determines that a health care provider that is an ACO or part of an ACO has committed information blocking, that provider would be barred from participating in the MSSP for at least one year. This may result in a health care provider being removed from an ACO or prevented from joining an ACO. In the instance where a health care provider is an ACO, this would prevent the ACO’s participation in the MSSP.

    SCOPE OF HEALTH CARE PROVIDERS IMPACTED BY PROPOSED DISINCENTIVES

    The information blocking regulations apply to a broad range of health care providers, including facilities such as nursing facilities, long-term care facilities, dialysis facilities, blood centers, ambulatory surgical centers, laboratories and pharmacies, and individual providers such as therapists and pharmacists. However, because only a subset of health care providers is subject to the requirements that are the basis for disincentives under the proposed rule (e.g., the Promoting Interoperability requirements), many health care providers would be, at least initially, excluded from the disincentives framework, even though they are “covered actors” under the Cures Act and the information blocking regulations. In the proposed rule, HHS included a request for information on additional appropriate disincentives HHS should consider for future rulemaking efforts that would apply to the health care providers excluded from the disincentive framework in this rulemaking.

    OIG INVESTIGATIVE AUTHORITIES, “REFERRALS” AND INTERSECTION WITH OIG CMP INFORMATION BLOCKING ENFORCEMENT RULE

    The application of disincentives to health care providers covered by HHS’s proposal turns on a determination by OIG that the health care provider committed information blocking, so to understand the potential impact of HHS’s proposed rule, it is important to understand OIG’s role in the information blocking ecosystem.

    The Cures Act granted OIG the authority to investigate information blocking claims against each type of covered actor—health care providers, certified health IT developers and HIN/HIEs. The Cures Act also granted OIG the authority to impose civil monetary penalties (CMP) against certified health IT developers and HIN/HIEs that violated the information blocking prohibition. OIG published its final rule implementing its CMP authority in the Federal Register in July 2023. That penalty authority, however, does not extend to the health care provider category of covered actors. Instead, the Cures Act requires OIG to refer health care providers that OIG determines have violated the information blocking prohibition to “the appropriate agency to be subject to appropriate disincentives.”

    From a procedural perspective, the proposed rule notes that OIG will coordinate with the “appropriate agency” to which OIG plans to make a “referral” during the pendency of OIG’s investigation and before actually making the referral in an effort to ensure that the agency is aware that OIG might make the referral. When OIG actually does make the referral, OIG will provide information about its determination of information blocking, including how the health care provider’s practice met the “intent element” of the prohibition, among other data related to the alleged misconduct.

    In the proposed rule, HHS identified OIG’s anticipated information blocking enforcement priorities for health care providers, which are identical to those OIG identified for certified health IT developers and HIN/HIEs except that OIG omitted actual knowledge from its enforcement priorities list for health care providers. This omission reflects the different knowledge standard in the statutory definition of information blocking for health care providers which must know that their alleged information blocking practice is likely to interfere with access, exchange or use of EHI to implicate the prohibition while health IT developers and HIN/HIEs must know or should know that their alleged information blocking practice is likely to interfere to implicate the prohibition.

    In connection with OIG’s final rule, OIG provided guidance describing its planned investigative process for entities subject to information blocking CMPs. Interestingly, OIG stated in its final rule that its discussion of its anticipated enforcement priorities and investigative process was limited to those entities subject to CMPs, and not applicable to health care providers that may be referred for appropriate disincentives. Although the proposed rule discusses OIG’s enforcement priorities for health care providers, it largely omits discussion of the underlying investigative process, including whether OIG’s process will similarly include an opportunity for health care providers to discuss an OIG investigation and explain why their conduct either did not implicate the information blocking prohibition, met an exception or was otherwise lawful. This is notable given the absence in the proposed rule of any appeal mechanism by which health care providers could challenge OIG’s information blocking determination. Although there may be some limited opportunities to appeal a disincentive, HHS specifically makes clear that ACO appeals under the MSSP regulations, at least, do not extend to OIG’s underlying information blocking determination. HHS does not discuss any other appeal avenues in the proposed rule.

    One would expect that OIG would need to engage with the health care provider to perform a reasonable investigation. But the OIG final rule’s disclaimer and the proposed rule’s omission of meaningful discussion about such interactions leaves open the question of what, if any, reasonable opportunities health care providers would have to make their case before being subjected to disincentives.

    “WALL OF SHAME” FOR INFORMATION BLOCKING

    The proposed rule would create a framework for public posts on ONC’s website about actors that OIG determines have committed information blocking. For health care providers subject to disincentives, the website would feature:

    • The health care provider’s name;
    • The provider’s business address (to ensure accurate provider identification);
    • The practice found to have been information blocking; the disincentive(s) applied; and
    • Where to find additional information, where publicly available, about the determination of information blocking.

    HHS also proposes to post similar information on ONC’s website about HIN/HIEs and certified health IT developers that OIG determines have committed information blocking (regardless of whether they resolved their CMP liability with OIG or were subject to a CMP). The proposal is intended to provide transparency into how information blocking conduct is impacting the nationwide health information technology infrastructure.

    This approach to transparency is similar to the HHS Office for Civil Rights’ notorious website that lists breaches of unsecured protected health information affecting 500 or more individuals (which is often referred to as the “wall of shame”). The transparency proposal is also an extension of the ONC’s existing website, Information Blocking Claims: By the Numbers, where it publishes statistics on the information blocking claims received through its “Report Information Blocking Portal” since April 5, 2021 (the information blocking compliance date). As of September 2023, ONC and OIG have received more than 800 claims of possible information blocking (including 685 claims against health care providers).

    NEXT STEPS

    If you would like to submit comments to the proposed rule before the January 2, 2024, deadline, contact any of the authors of this On the Subject or your regular McDermott lawyer or McDermott+Consulting advisor. Health care providers also should consider reviewing their information blocking policies and practices now so that they are ready for a future final rule.

    Authors

    James A. Cannatti III

    Partner

    Washington, DC

    Daniel F. Gottlieb

    Partner

    Chicago

    More insights

  • Italian Tax Reform | Reshoring

    Italian Tax Reform | Reshoring

    ARTICLE / CLIENT ALERT

    Italian Tax Reform | Reshoring

    November 13, 2023

    Read time: 9 min

    Key takeaways
    Overview

    On October 16, 2023, the Council of Ministers approved, in preliminary examination, the draft of a legislative decree implementing the tax reform on international taxation. The draft decree must now acquire the opinions of the relevant parliamentary committees before officially coming into force.

    In our previous alerts, we reviewed the main measures of interest to businesses and in particular reviewed the new residence provisions for individuals, companies and entities.

    In this latest alert we will explore the innovation ushered in by the new so-called ‘reshoring’ of ‘economic activities’ in Italy.

    The new ‘reshoring’ provisions will apply as of the tax period following the tax period in progress on the date of final approval of the legislative decree (e.g., as of 2024, if the legislative decree scheme is approved, as planned, by December 31, 2023).

    The actual entry into force of the provisions is, however, conditional upon the authorization by the European Commission.

    In depth

    Reshoring of Economic Activities

    Article 6 of the draft legislative decree provides for a special tax incentive aimed at encouraging the transfer of ‘economic activities’ to Italy. Both the heading of Article 6 and the Illustrative Report on the decree allude to this incentive, which pertains to a tax incentive aimed at favouring the carrying out in Italy of ‘economic activities’ previously conducted in a foreign country, other than a State belonging to the EU or the European Economic Area (EEA).

    This measure follows current similar initiatives already underway in other countries, chiefly the United States, where, however, ‘reshoring‘ measures have focused on certain sectors, considered strategic for growth, such as energy. The Italian decree differs in that it pertains to all “economic activities” regardless of sector.

    It is envisaged that income deriving from business activities (or from the exercise of arts and professions exercised in an associated form) carried out in a foreign country not belonging to the EU or the EEA and transferred to Italy would be exempt, for income tax and IRAP purposes, for 50% of the relevant amount:

    • the relief applies in the current tax period at the time of the transfer to Italy and in the following five tax periods;
    • ‘economic activities’ (already) exercised in the territory of the State in the 24 months preceding the transfer to Italy are not considered as eligible.

    The legislation raises numerous questions for operators, starting with the objective scope of application.

    Economic Activities

    The scope of ‘economic activities’ potentially affected by the ‘reshoring’ legislation is rather broad.

    As mentioned, the draft legislative decree makes general reference to income derived from ‘business activities‘ carried out in a foreign country outside the EU or EEA and transferred to Italy.

    Given this framework, the new regime might apply in the case of the transfer of the registered office in Italy of non-EU and EEA foreign companies.

    The draft legislative decree does not make any specific allusion to the possible ‘combined’ application of the provisions of Article 166-bis of the Consolidated Income Tax Law (TUIR), concerning the step-up of tax basis upon entry, in the event that the transfer of the registered office in Italy is made by a party resident in a country that allows an effective exchange of information (the so-called ‘white list‘ referred to in the Ministerial Decree of September 4, 1996, as amended in the medium term).

    General opinion is that the reference in the draft legislative decree to ‘income‘ deriving from business activities transferred to Italy does not preclude the possible combined application of ‘reshoring‘ relief with the so-called ‘step-up‘ of the tax values of the transferred assets already provided for in Article 166-bis of the TUIR. Thus, higher depreciation and/or lower capital gains could be allowed, to further reduce the tax base excluded from taxation by 50% of the relevant amount.

    In any case, the application of the ‘reshoring‘ relief (in combination – or not – with the ‘step-up‘ regime provided for in Article 166-bis of the Consolidated Income Tax Act) will have to be assessed taking into account the other provisions contained in the draft legislative decree on ‘international taxation’, in particular those relating to the implementation of the so-called ‘Pillar 2‘, and the possible QDMTT (Qualifying Domestic Minimum Top-Up Taxes) that could be applied to profits subject to IRES and IRAP at an effective rate of less than 15%.

    The transferred ‘economic activities’ subject to relief also include business activities carried out by companies belonging to groups. For these particular purposes, the “stand alone” origin (non-EU and EEA) of the “economic activities” transferred to Italy should be relevant, regardless of the composition of the group to which it belongs.

    The reference in the draft legislative decree to ‘economic activities’ would by definition include any transfer to Italy of business branches as they produce business income. Take as facilitated, for example, the transfer of a ‘production line’ in a factory already existing in Italy.

    The attractiveness of this new incentive will be tempered by the interpretation of the Revenue Agency.

    It must be said that, in the context of European Union law, ‘economic activity’ is considered to be ‘any activity consisting in offering goods or services on a given market‘ (CJEU, judgment of June 18, 1998, Case C-35/96; CJEU, judgment of 30 March 2000, Case C-513/93; CJEU, judgment of January 10, 2006, Case C-222/04).

    For its part, the Italian Revenue Agency (Ruling No. 460 of October 31, 2019) has clarified that the regime for the valuation of “inbound” assets, pursuant to Article 166-bis of the TUIR, is to be understood as referring to all persons having a business income, according to the domestic legal system, regardless of the economic activity carried out by the same. Consequently, qualification as a holding company would not be an obstacle to the applicability of the relevant regime.

    Similar considerations should apply to the ‘reshoring‘ discipline, given the rule’s reference to ‘economic activities’ and ‘income from business activities‘.

    The question arises as to whether (and how) the “reshoring” regime might apply to and benefit entities which are already established in Italy which undergo a “conversion” where their “functional” profile is modified (and the assets available) in the “value-chain” of the group. We might take as an example the case of the conversion of a “low-risk distributor” into a “fully-fledged” entity, perhaps carrying out manufacturing activities and even so far as commissioning them to third parties.

    The taxpayer is required to maintain separate accounting records suitable for verifying the correct determination of the income and value of the net production eligible for relief.

    In the case of ‘economic activities’ transferred to Italy and generating 50% exempt foreign source income – e.g. royalties – the foreign tax credit abroad must be reduced accordingly, as provided for in Article 165(10) of the TUIR (see Principle of Law No. 15 of May 29, 2019).

    It is worth recalling that “reshoring” operations are potentially included among the “relevant investments” for the presentation of the so-called “new investments ruling”. Circular No. 7/E of 28 March 2023 of the Italian Revenue Agency refers, in this regard, to “operations (i) of “repatriation” of assets by persons who have previously relocated abroad or (ii) of return of such persons (so-called “in-shoring” or “reshoring”), as well as of transfer of tax residence in Italy of foreign persons, provided that such investment is quantifiable (today) in at least €15 million and positive employment effects are produced“.

    Activities Carried Out in the Previous 24 Months

    It is envisaged that ‘economic activities’ transferred to Italy may fall within the scope of ‘reshoring‘, provided that they have not been exercised in the territory of the State in the preceding 24 months.

    This preclusion is evidently aimed at avoiding transfers abroad of ‘economic activities’ instrumental to their subsequent ‘repatriation’ for the sole purpose of benefiting from the new incentive regime.

    Therefore, ‘economic activities’ which have never been exercised in Italy, as well as those already exercised in Italy at a time earlier than the ‘surveillance’ period of 24 months prior to the transfer to Italy, may benefit from the special ‘reshoring‘ regime.

    The possible ‘repatriation’ to Italy of foreign permanent establishments of Italian companies (regardless of the regime applied to them, i.e. branch exemption or tax credit) may not fall under this exclusion, since the draft legislative decree expressly refers to activities ‘exercised in the territory of the State in the 24 months preceding their transfer’.

    Recapture

    The advantage ceases to apply if, in the five tax periods following the expiry of the incentive (which lasts, as a rule, six tax periods, i.e. the one in which the transfer takes place and the following five tax periods), the beneficiary transfers out of the territory of the State, even partially, the ‘economic activities’ that were the subject of the previous transfer to Italy.

    In the event that the beneficiary is a so-called ‘large enterprise’ (Commission Recommendation 2003/361/EC) the ‘recapture‘ period is extended to 10 years following the expiry of the incentive.

    Similarly, to what is provided for the ‘recapture‘ period following the expiry of the preferential period, it should be concluded that the taxpayer also forfeits the advantage if they transfer the ‘economic activities’ abroad in the five tax periods following the ‘reshoring‘ in Italy. In essence, the transferred “economic activities” are “bound” to the territory of the State for 10 years (15 years, in the case of “large enterprises”), in addition to the tax period underway at the time of the “reshoring” in Italy.

    It must be said that, with respect to the first draft circulated, the ‘bulleted’ version of the legislative decree scheme provides for the forfeiture of the benefit in the event of a generic transfer of the activities outside the territory of the State. The first version of the legislative decree scheme referred, instead, to the transfer of the ‘economic activities’ to a non-EU and EEA State. The question arises as to whether the forfeiture condition now extended to any transfer abroad is consistent with the principle of freedom of establishment under Article 49 TFEU.

    Forfeiture of the relief is also foreseen in the case of ‘partial’ transfer abroad of the ‘economic activities’ that were the subject of the previous transfer.

    The considerations made above with respect to the identification of qualified ‘economic activities’ also apply in the case of migration from the national territory. It is unclear whether a functional reorganisation that, by affecting the ‘value-chain‘, reduces functions and/or risks in favour of non-resident entities can be considered a cause for disqualification.

    In the event of forfeiture, the tax authorities will recover the unpaid taxes, as a result of the facilitation scheme, with interest but without penalties.

    Authors
    More insights

  • Chambers Insolvency 2023 I Global Practice Guide

    Chambers Insolvency 2023 I Global Practice Guide

    ARTICLE / REPORT

    Chambers Insolvency 2023 I Global Practice Guide

    November 23, 2023

    Read time: 2 min

    Overview

    Corporate insolvencies in Germany are on the rise after years of decline. Dr. Matthias Kampshoff, Dr. Uwe Goetker, Dr. Marc Oberhardt, Dr. Björn Biehl and Dr. Benedikt Schulz delve into the factors behind this trend and the innovative solutions being adopted. View the Global Chambers Practice Guide and the chapter on insolvency.

    In depth
    Tabs

    Dr. Matthias Kampshoff

    Partner

    Düsseldorf

    Dr. Uwe Goetker

    Partner

    Düsseldorf

    More insights
    Endnotes

  • CMS Proposes to Prohibit Overrides in Medicare Advantage

    CMS Proposes to Prohibit Overrides in Medicare Advantage

    ARTICLE / CLIENT ALERT

    CMS Proposes to Prohibit Overrides in Medicare Advantage

    November 9, 2023

    Read time: 5 min

    Key takeaways
    Overview

    On November 6, 2023, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule regarding Contract Year (CY) 2025 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit Programs. Among other proposals, CMS proposed significant changes to longstanding rules on permissible payment structures for agents and brokers. Some of the proposed changes would likely go into effect in 2024 (once the final rule is effective), while others would not be effective until the 2025 contract year.

    The rule will be published in the Federal Register on November 15, 2023, and comments are due by January 5, 2024.

    In depth

    OVERVIEW: KEY PROPOSALS RELATED TO MA ARRANGEMENTS WITH AGENTS AND BROKERS

    CMS is proposing to make the following changes:

    • Prohibit override/administrative fees paid to agents and brokers (either directly by MA plans or indirectly by field marketing organizations (FMOs)) outside of the fair market value (FMV) enrollment compensation limits established by CMS
    • Redefine “compensation” so that the FMV compensation limits expressly include certain types of expenses (e.g., mileage, venue rental, snacks, materials) that previously could be separately reimbursed by plans
    • Establish a single FMV compensation rate for all plan types, replacing the current FMV compensation ceilings for different types of plans
    • Prohibit contract terms between Medicare Advantage organizations (MAOs) and agents, brokers or other third-party marketing organizations (TPMOs) that may interfere with the agent’s or broker’s ability to assess and recommend the most suitable plan for a beneficiary

    Each of these proposals is discussed in greater detail below.

    PROHIBITING OVERRIDE/ADMINISTRATIVE FEES PAID TO AGENTS AND BROKERS; REDEFINING “COMPENSATION”

    CMS has previously permitted MA and Part D plan sponsors to pay agents and brokers for administrative services other than enrollment (such as training, customer service, agent recruitment, operational overhead or assistance with completion of health risk assessments) outside of the compensation limits set by CMS, provided that these administrative payment amounts are consistent with FMV for the services. CMS’s current regulations expressly permit these administrative fees to be paid on a per-enrollment basis. These are often paid to FMOs or other general agencies and commonly referred to in the industry as “overrides.”

    CMS now proposes to prohibit these separate administrative payments and require that such amounts be subject to the annual FMV compensation limits set by CMS. Specifically, CMS would require that all payments to agents or brokers that are tied to, related to, or are for services conducted as part of the relationship associated with the enrollment into an MA or Part D plan must be included under compensation, including payments for certain activities previously excluded under the definition of compensation (e.g., reimbursement for mileage to and from appointments with beneficiaries, and for actual costs associated with sales appointments such as venue rent, snacks and materials). CMS proposes to increase the FMV by $31 beginning in 2025 to reflect what CMS considers to be the value of administrative compensation for these types of services, with this amount subject to annual updates according to FMV update requirements.

    Under CMS’s proposal, the agency would delete the regulatory provision at 42 CFR 422.2274(e)(2) that currently allows administrative fees to be paid on a per-enrollment basis, and the deletion of that provision may be effective as of the effective date of the final rule (which would likely be in 2024). Such a revision could potentially affect MA and Part D plans’ administrative services arrangements with certain entities that currently are paid on a per-enrollment basis for administrative services.

    ESTABLISHING A SINGLE FMV COMPENSATION RATE

    Under current regulations, compensation for agents and brokers may be paid at a rate determined by the MA or Part D plan sponsor, but may not exceed caps that CMS calculates each year based on FMV (e.g., CY 2023 FMV caps are $601 for each MA initial enrollment, $301 for an MA renewal enrollment, $92 for each Part D initial enrollment, and $46 for a Part D renewal enrollment). CMS now proposes to set a single agent and broker compensation rate for all plans, reflecting a simplified structure for agent and broker compensation. CMS would also eliminate the requirement for plan sponsors to report independent agent and broker fees each year, because this new single compensation rate would apply in all cases.

    PROHIBITING CERTAIN CONTRACT TERMS

    Beginning in 2025, CMS proposes to prohibit contract terms between MA and Part D plan sponsors (on the one hand) and agents, brokers or TPMOs (on the other hand) that indirectly or directly incentivize agents or brokers in a manner that could impede their ability to impartially evaluate and suggest the most suitable plan for a beneficiary’s healthcare needs. Examples of contract terms CMS views as problematic include those that:

    • Tie the compensation, renewal or other aspects of a plan’s contract with an agent, broker or FMO to preferentially high enrollment rates or achievement of set enrollment targets
    • Arrange for bonuses or additional payments from MA or Part D plan sponsors to an FMO that are intended to be passed on to agents or brokers based on enrollment volume in plans sponsored by those MA or Part D plan sponsors
    • Arrange for an FMO to provide an agent or broker with leads or other incentives based on previously enrolling beneficiaries into specific plans, for reasons unrelated to the beneficiaries’ healthcare needs
    Authors

    Mimi Alexandre

    Partner

    Washington, DC

    Jeremy Earl

    Partner

    Washington, DC

    Kate McDonald

    Partner

    Washington, DC

    More insights

  • NYDFS Finalizes Amendments to Cybersecurity Regulation Impacting Financial Services Companies

    NYDFS Finalizes Amendments to Cybersecurity Regulation Impacting Financial Services Companies

    ARTICLE / CLIENT ALERT

    NYDFS Finalizes Amendments to Cybersecurity Regulation Impacting Financial Services Companies

    November 9, 2023

    Read time: 6 min

    Key takeaways
    Overview

    On November 1, 2023, the New York Department of Financial Services (NYDFS) amended Part 500, the cybersecurity regulation. These updates follow numerous NYDFS enforcement actions and other new cybersecurity rules, such as the updated US Securities and Exchange Commission cybersecurity reporting requirements and the proposed cybersecurity audit regulations under the California Consumer Privacy Act.

    The new NYDFS rules mandate increased board oversight, “independent” audits for large companies, incident response planning and testing (e.g., tabletops), maintained asset inventories, more extensive RNYDFS reporting and many new technical controls. Businesses regulated by the NYDFS (including financial institutions and insurance companies) must certify they comply with most requirements by April 2024. Reporting requirements, however, will take effect before April 2024.

    Extensive work will be needed in a short amount of time, so covered entities should begin updating policies, procedures and incident response plans, conducting tabletop exercises, launching new cybersecurity training, and preparing management and the board for their new oversight activities. Below is a non-exhaustive summary of the major requirements.

    In depth

    Introduction of “Class A companies”: The updated cybersecurity regulations create a new category for larger corporations called “Class A companies.” These entities are held to stricter standards.

    • Class A companies include covered entities with at least $20 million in gross annual revenue from business operations in New York and either more than 2,000 employees or more than $1 billion in gross annual revenue from business operations in all states.
    • Class A companies are now required to conduct audits of their cybersecurity programs; those audits must be independent. Notably, an independent audit can still be conducted by an internal auditor if the auditor is free from influence (not unlike a data protection officer employed under the General Data Protection Regulation). This requirement may make it challenging for companies to conduct legally privileged audits.

    New board/c-suite obligations: Executives, board members and senior officers now have specific responsibilities to oversee the covered entities’ cybersecurity program. These internal governance bodies are crucial to the proper functioning of a cybersecurity program and highlight regulators’ increased focus on the board’s role in cybersecurity oversight.

    • Chief information security officers are now required to report to the board or other equivalent bodies on material cybersecurity issues (e.g., significant cybersecurity events or changes to cybersecurity programs).
    • The board or other equivalent bodies now have specific obligations to oversee cybersecurity risk management, including reviewing regular management reports and confirming that the cybersecurity program is properly funded.
    • Boards and equivalent bodies must be qualified to conduct these oversight activities, including by undergoing training as necessary.

    Cybersecurity policy updates: Covered entities must now document and maintain several additional cybersecurity policies and procedures (or ensure that their existing cybersecurity policies and procedures cover these new areas).

    • Covered entities must maintain policies governing data retention, end-of-life management, remote access, security awareness and training, incident notification and vulnerability management.
    • Covered entities must document procedures implementing each policy.
    • Policies must be approved annually by the board or other equivalent bodies.

    Enhanced technical security controls: The cybersecurity regulations impose additional technical requirements.

    • Risk assessments must be conducted at least annually.
    • More robust access management requirements are required, including annual reviews of all user access privileges.
    • Multifactor authentication is now required (not just suggested) for any individual accessing a covered entity’s information systems. There is a narrow carve-out for entities below certain headcount, revenue or asset thresholds, but even those entities must use multifactor authentication in designated situations, such as remote access.
    • Covered entities must monitor and filter web traffic and email to protect against malicious code.
    • Cybersecurity awareness training must be provided annually.

    Incident response plans and business continuity management: Covered entities must have documented business continuity and disaster recovery (BCDR) plans and include more specific content in incident response plans (IRPs).

    • IRPs must now identify how covered entities will recover backups and include instructions for a root cause analysis following an incident.
    • Covered entities must maintain BCDR plans that identify critical business functions, include communication plans in the event of cybersecurity-related disruption, detail procedures for backups and recovery of impacted data, and other requirements.
    • IRPs and BCDR plans must be tested annually (e.g., via a tabletop exercise).

    Asset inventories: Covered entities must now maintain asset inventories.

    • Asset inventories must include the owner, location, classification or sensitivity, support expiration date and recovery time objectives.
    • Covered entities must document how often they update and validate the asset inventories.

    Notice requirements for cybersecurity incidents: Covered entities must notify the superintendent about additional cybersecurity incidents.

    • Superintendent notice is now required for a broader range of cybersecurity incidents, including a ransomware attack in a material part of the company’s information systems.
    • For any extortion payments, covered entities must provide electronic notice to the superintendent within 24 hours of the payment and provide additional detailed information within 30 days.

    Exemptions: Limited exemptions from these requirements are available in slightly more circumstances, such as if a company meets any of the following criteria:

    • If it has fewer than 20 employees (instead of 10).
    • If it recorded less than $7.5 million in gross annual revenue in each of the last three fiscal years (instead of $5 million).
    • If it recorded less than $15 million in year-end total assets (instead of $10 million).

    Deadlines for compliance: Unless otherwise specified, the amendments will take effect on April 29, 2024. The exceptions to this compliance date are as follows:

    Timeline from November 1, 2023 Compliance Area Expected
    30 days
    • Notices to NY DFS in the event of a Cybersecurity Incident
    One year
    • Cybersecurity governance requirements
    • Additional encryption requirements
    • IRP and BCDR plan updates
    • Limited exemptions take effect
    18 months
    • Automated vulnerability scans
    • Additional access management obligations
    • Implementation of risk-based controls to protect against malware, like email scanning
    • For Class A companies, implementation of an endpoint detection and response solution
    Two years
    • Additional multifactor authentication requirements
    • Asset inventory requirements

    Given the significant number of new requirements, covered entities should act quickly to assess any gaps and develop work plans to fill them. For assistance with conducting an assessment or implementing the new requirements, please contact the authors or your regular McDermott lawyer.

    The authors thank John Ying and Heidi Steele for their invaluable input on this article.

    Authors

    Kathryn Linsky

    Partner

    New York – One Vanderbilt Avenue

    Elliot R. Golding

    Partner

    Washington, DC

    More insights

  • Sorry—No Finality, No Injunction, No Appellate Jurisdiction

    Sorry—No Finality, No Injunction, No Appellate Jurisdiction

    ARTICLE

    Sorry—No Finality, No Injunction, No Appellate Jurisdiction

    Nov 9, 2023

    Read time: 4 min

    Key takeaways
    Overview

    The US Court of Appeals for the Third Circuit dismissed an appeal from the denial of a motion under the Defend Trade Secrets Act (DTSA) for an ex parte seizure order, explaining that such orders are not final, not effectively injunctive and that the DTSA does not independently provide appellate jurisdiction to review such orders. Janssen Prod., L.P. v. eVenus Pharms. Lab’ys Inc., Case No. 22-2426 (3d Cir. Oct. 17, 2023) (Porter, Freeman, Fisher, JJ.)

    In 2015, the US Food & Drug Administration (FDA) approved Janssen’s drug Yondelis—a stable, injectable version of the cancer drug trabectedin—for use in certain cancer patients. Janssen asserts that its data, specifications and methods for manufacturing Yondelis are trade secrets. After Janssen received FDA approval for Yondelis, eVenus sought FDA approval for a generic version of Yondelis. Janssen filed a lawsuit against eVenus (under the Hatch-Waxman Act) for patent infringement. During discovery, Janssen obtained documents that allegedly demonstrated that eVenus misappropriated Janssen’s trade secrets. Janssen then filed the current lawsuit against eVenus seeking relief for eVenus’s alleged trade secret misappropriation under the DTSA.

    During discovery, Janssen found that eVenus spoliated evidence. In response, Janssen filed a motion for an ex parte seizure under the DTSA, requesting that the district court order the seizure of eVenus’ network servers and stored data, and the laptops and cell phones of certain eVenus employees and ex-employees. The district court denied Janssen’s ex parte seizure motion. Janssen appealed.

    The Third Circuit dismissed the appeal, concluding that it lacked jurisdiction over Janssen’s appeal for two reasons.

    First, the Third Circuit found that it lacked appellate jurisdiction because the district court’s denial of Janssen’s ex parte seizure motion was not a final judgment and did not meet any of the limited exceptions to the final judgment rule.

    One limited exception to appellate jurisdiction under the final judgment rule is review of a lower court’s refusal to order injunctive relief. However, as the Third Circuit explained, an ex parte seizure order under the DTSA is not effectively injunctive and therefore does not fall under the injunction exception. The Court explained that refusal to grant an ex parte seizure order does not satisfy the first two prongs of the Court’s three-part functional injunction test, which require that an order be “directed to a party” and may be enforced by contempt. Regarding the first prong, the Court noted that DTSA seizure orders are not “directed to a party” because the DTSA requires law enforcement officials—and not a party—to execute any ex parte seizure order. Regarding the second prong, no party can be held in contempt for failing to comply with an order that does not direct it to do anything. Therefore, the district court’s order did not effectively deny an injunction.

    Second, the Third Circuit analogized DTSA seizure orders with seizure orders under the Lanham Act in terms of statutory construction. As the Court explained, in the Lanham Act, ex parte seizure provisions are part of its “injunctive relief” section. In contradistinction, Congress did not provide any link between the DTSA’s civil seizure provisions and injunction provisions. The Court further noted that the DTSA includes provisions that suggest Congress intended ex parte seizure orders under the DTSA to be distinct from injunctions. Finally, the Court noted that the DTSA was enacted in 2016 as an amendment to the Economic Espionage Act (EEA). As the Court observed, Congress’s express grant of appellate jurisdiction over certain interlocutory appeals in the EEA stands in contrast to the lack of such express jurisdictional authority over DTSA ex parte seizure rulings.

    Authors
    More insights
    Endnotes